Medrad last week announced financial results for its fiscal 1995 (end-January) that saw revenues increase9% and net earnings up as well. The Pittsburgh-based company recordedrevenues for the fiscal year of $78.3 million, compared to $71.7million in the
Medrad last week announced financial results for its fiscal 1995 (end-January) that saw revenues increase9% and net earnings up as well. The Pittsburgh-based company recordedrevenues for the fiscal year of $78.3 million, compared to $71.7million in the prior year. Net earnings in 1995 will be approximately$1.15 per share, compared to 92¢ per share for the same perioda year ago.
Medrad also announced that it has created separate businessunits for its two major businesses, vascular injection systemsand MRI surface coil products. Each unit will have its own dedicatedmanagement team and new product development functions, the companyreported.
Stay at the forefront of radiology with the Diagnostic Imaging newsletter, delivering the latest news, clinical insights, and imaging advancements for today’s radiologists.
Study Shows Enhanced Diagnosis of Coronary Artery Stenosis with Photon-Counting CTA
July 10th 2025In a new study comparing standard resolution and ultra-high resolution modes for patients undergoing coronary CTA with photon-counting detector CT, researchers found that segment-level sensitivity and accuracy rates for diagnosing coronary artery stenosis were consistently > 89.6 percent.
FDA Expands Approval of MRI-Guided Ultrasound Treatment for Patients with Parkinson’s Disease
July 9th 2025For patients with advanced Parkinson’s disease, the expanded FDA approval of the Exablate Neuro platform allows for the use of MRI-guided focused ultrasound in performing staged bilateral pallidothalamic tractotomy.